Based on preclinical testing, WP1732 is a potential breakthrough discovery, a new fully water-soluble p-STAT3 inhibitor technology complementary to orally bioavailable non-water-soluble WP1066. STAT3 inhibitors are an essential part of our efforts to develop new cancer treatments that effectively target highly resistant tumors.

We believe this expanded array of effective STAT3 inhibitors could improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer. Specifically, our drug development partner has stated that preclinical evidence suggests WP1732, the injectable new molecule, is capable of inhibition of oncogenic transcription factors similarly to orally administered WP1066. We believe the significantly increased solubility of WP1732 may make it a good choice for administration via standard intravenous (IV) injection. Preclinical animal testing in connection with human trials has also shown that WP1732 is capable of disproportionately high accumulation in the pancreas, making it a promising candidate for treating pancreatic cancer, one of the most resistant and deadly forms of cancer.